Katherine E. Ware
Affiliations: | 2008-2012 | Craniofacial Biology | University of Colorado Anschutz Medical Campus, Denver, Aurora, CO |
Google:
"Katherine Ware"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Jolly MK, Ware KE, Xu S, et al. (2019) E-cadherin represses anchorage-independent growth in sarcomas through both signaling and mechanical mechanisms. Molecular Cancer Research : McR |
| Xu S, Ware KE, Ding Y, et al. (2019) An Integrative Systems Biology and Experimental Approach Identifies Convergence of Epithelial Plasticity, Metabolism, and Autophagy to Promote Chemoresistance. Journal of Clinical Medicine. 8 |
| Vaishnavi A, Schubert L, Rix U, et al. (2017) EGFR mediates responses to small molecule drugs targeting oncogenic fusion kinases. Cancer Research |
| Wynes MW, Hinz TK, Gao D, et al. (2014) FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3299-309 |
| Ware KE, Hinz TK, Kleczko E, et al. (2013) A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis. 2: e39 |
| Marshall ME, Hinz TK, Kono SA, et al. (2011) Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5016-25 |
| Ware KE, Marshall ME, Heasley LR, et al. (2010) Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. Plos One. 5: e14117 |
| Keating AK, Kim GK, Jones AE, et al. (2010) Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Molecular Cancer Therapeutics. 9: 1298-307 |
| Kono SA, Marshall ME, Ware KE, et al. (2009) The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 12: 95-102 |
| Marek L, Ware KE, Fritzsche A, et al. (2009) Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Molecular Pharmacology. 75: 196-207 |